BioNTech SE (BNTX)
| Market Cap | 27.11B |
| Revenue (ttm) | 3.39B |
| Net Income (ttm) | -520.75M |
| Shares Out | 239.74M |
| EPS (ttm) | -2.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 924,764 |
| Open | 110.76 |
| Previous Close | 111.34 |
| Day's Range | 109.80 - 115.34 |
| 52-Week Range | 76.53 - 131.49 |
| Beta | 0.17 |
| Analysts | Strong Buy |
| Price Target | 143.50 (+26.9%) |
| Earnings Date | Nov 4, 2024 |
About BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinic... [Read more]
Financial Performance
In 2023, BioNTech SE's revenue was 3.82 billion, a decrease of -77.94% compared to the previous year's 17.31 billion. Earnings were 930.30 million, a decrease of -90.14%.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for BNTX stock is "Strong Buy." The 12-month stock price forecast is $143.5, which is an increase of 26.90% from the latest price.
News
US FDA lifts partial clinical hold on BioNTech cancer drug study
BioNTech SE said on Friday it has been informed by its partner OncoC4 that the U.S. Food and Drug Administration has lifted the partial clinical hold on its late-stage trial studying its drug for a ty...
Why Is BioNTech Stock Trading Higher On Friday?
On Thursday, Duality Biologics revealed the first data from a global Phase 1/2a trial of BNT324/DB-1311, which it co-developed with BioNTech SE BNTX.
BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It.
Evercore ISI analyst Cory Kasimov upgrades the German drugmaker's stock to Outperform from In Line.
Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head
In the 2024 presidential election's latest impact on the stock markets, shares of several vaccine makers were down Friday morning following the nomination of Robert F. Kennedy Jr. to head the Departme...
Pharma shares hit as Trump picks RFK Jr to lead health department
Choice of vaccine critic knocks some of world's biggest drugmakers including Moderna, AstraZeneca and GSK
Vaccine maker stocks fall on reports Trump plans to tap RFK Jr. to lead HHS
Shares of vaccine makers fell on reports that President-elect Donald Trump is expected to nominate Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Servic...
BioNTech buys China's Biotheus to support oncology strategy
German drugmaker BioNTech has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and gain full global rights to the bispecific antibody candidate BNT327, it said on We...
BioNTech to Acquire Biotheus to Boost Oncology Strategy
MAINZ, Germany, November 13, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Biotheus (“Biotheus”) today announced the signing of a definitive agreement for the acquisition of Bi...
BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
Goldman Sachs has upgraded BioNTech SE BNTX, citing the company's BNT327, an immuno-oncology asset in clinical development across multiple solid tumors.
BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
BioNTech SE's stock saw a spike in September due to positive data from Summit Therapeutics' ivonescimab, which has a similar mechanism to BioNTech's BNT327. BioNTech's Q3 earnings showed improved reve...
Why most healthcare stocks are falling with Trump's win, with some exceptions
Investors are worried about what a Trump administration means for hospital operators and vaccine makers, but are optimistic about the fate of Medicare Advantage plan providers.
BioNTech SE (BNTX) Q3 2024 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Chief Executive Officer & Co-F...
BioNTech Variant-adapted COVID-19 Vaccines Do Well In Q3
On Monday, BioNTech SE BNTX reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 million euros a year ago.
BioNTech lowers full-year revenue outlook on COVID-19 seasonality, inventory write-downs
German drugmaker BioNTech on Monday lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels, inventory write-downs and Pfizer charges.
BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
Conference call and webcast scheduled for November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET)
BioNTech to Host Innovation Series R&D Day on November 14, 2024
MAINZ, Germany, October 31 , 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company's Innovation Series R&D Day at 10:30 a.m. Eastern St...
BioNTech's Oncology Gamble: High Stakes, Big Potential
BioNTech's oncology assets, including BNT327/PM8002, show promising results, with a notable 39.3% ORR in PD-L1-negative EGFR-mutated NSCLC patients. BioNTech's stock has risen by 24% since March, outp...
BioNTech to Report Third Quarter 2024 Financial Results and Corporate Update on November 4, 2024
MAINZ, Germany, October 21, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the third quarter 2024 on Monday, November 4, 2024...
Health Rounds: mRNA vaccine shows promise against C. difficile in animal study
Researchers are developing what they hope will be the first successful vaccine against the highly contagious and difficult-to-treat Clostridioides difficile bacteria, using the technology behind the r...
Pfizer, BioNTech win bid to invalidate CureVac's UK COVID vaccine patents
Pfizer and its German partner BioNTech on Tuesday won their attempt to invalidate two of rival CureVac's patents at London's High Court.
BioNTech (BNTX) Presents at Innovation Series: AI Day
BioNTech SE (NASDAQ:BNTX) Company Conference Call October 1, 2024 9:00 AM ET Company Participants Karim Beguir - Chief Executive Officer, InstaDeep Uğur Şahin - Chief Executive Officer, BioNTech Ryan...
BioNTech Highlights AI Capabilities and R&D Use Cases at Inaugural AI Day
LONDON, United Kingdom, October 1, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), alongside its artificial intelligence (“AI”) subsidiary InstaDeep Ltd . (“InstaDe...
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that the Committee for Medicinal Products for Human Use (CHMP) ...
BioNTech Is More Than a Covid-19 Stock. It's Having a Great September.
Recently BioNTech has been boosted a wave of enthusiasm over another company's cancer drug, which has turned the biopharma industry upside down.